Lantheus Presents Data from Two Pivotal Phase 3 Studies of TAUKLARIFY (Florquinitau F 18 Injection) PET Imaging in Early Alzheimer’s Disease
PharmaLogic to Acquire Lantheus' CDMO Business and Springfield, New Jersey Manufacturing Facility
Lantheus Holdings: Q3 Earnings Snapshot
Lantheus Welcomes CMS CY27 Final Rule Advancing Access to Diagnostic Radiopharmaceuticals
Lantheus Reports Third Quarter 2026 Financial Results
Lantheus Holdings Q3 Adj. EPS $1.68 Beats $1.24 Estimate, Sales $389.913M Beat $359.757M Estimate
Lantheus Announces Presentation of Data at the 2026 Clinical Trials on Alzheimer’s Disease Annual Meeting
Mizuho Downgrades Lantheus Holdings to Neutral, Lowers Price Target to $109
Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu (piflufolastat F 18)
Lantheus Receives Transitional Pass-Through Payment Status For PYLARIFY TruVu Injection From Centers For Medicare & Medicaid Services, Effective Oct. 1
Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer
Lantheus Holdings Announces First Patient Dosed In SPARROW NCT07831824, Phase 2/3 Registrational Trial Evaluating LNTH-2401
Lantheus Holdings (LNTH) Could Be 7% Undervalued On BRAVNETSA Approval
Lantheus Holdings (LNTH) Stock May Be 14% Undervalued On FDA Approval
Strong Earnings, FDA Approval, and Takeover Interest Drive Lantheus Holdings’ (LNTH) Rally
3 Reasons LNTH is Risky and 1 Stock to Buy Instead
Lantheus Receives Final FDA Approval for BRAVNETSA™ (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA has Determined to be Bioequivalent and Therapeutically Equivalent to LUTATHERA® for the Treatment of GEP-NETs
Curium acquisition of Lantheus backed by $5.375B of debt financing
Healthcare Equipment and Supplies Stocks Q2 Recap: Benchmarking Lantheus (NASDAQ:LNTH)
Lantheus Announces FDA Approval of TAUKLARIFY™ (Florquinitau F 18 Injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer’s Disease
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.